Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318429 | 0.92 | CTSK (0.48) | MMP13CTSKKMT2AALDH1A1F2 | |
| SCHEMBL17318395 | 0.91 | MMP13 (0.47) | MMP13PTGER4CTSKKMT2AALDH1A1 | |
| SCHEMBL17318458 | 0.90 | MMP13 (0.47) | MMP13PTGER4CTSKKMT2AALDH1A1 | |
| SCHEMBL20285807 | 0.90 | KMT2A (0.49) | MMP13CTSKKMT2AALDH1A1CYP3A4 | |
| SCHEMBL17318470 | 0.89 | MMP13 (0.47) | MMP13PTGER4KMT2AALDH1A1F2 | |
| SCHEMBL17318440 | 0.89 | KMT2A (0.54) | CTSKKMT2AALDH1A1F2 | |
| SCHEMBL19051239 | 0.87 | KMT2A (0.46) | MMP13PTGER4CTSKKMT2AALDH1A1 | |
| SCHEMBL19051217 | 0.86 | KMT2A (0.45) | MMP13PTGER4KMT2AALDH1A1F2 | |
| SCHEMBL17318457 | 0.86 | NR1H4 (0.57) | ALDH1A1F2HSD17B10PKM | |
| SCHEMBL19051234 | 0.85 | KMT2A (0.46) | MMP13PTGER4KMT2AALDH1A1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-3152188-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188152-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407382-B2 | EP4 agonists as therapeutic compounds | PTGER4, PTGER1, PTGER3 | MMP13 2376/4885PTGER4 1/4885CTSK 2892/4885 |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | MMP13 3012/4885PTGER4 1/4885CTSK 3050/4885 |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | MMP13 3012/4885PTGER4 1/4885CTSK 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.